Ensysce Biosciences, Inc. (ENSC)

NASDAQ: ENSC · IEX Real-Time Price · USD
0.546
+0.064 (13.36%)
At close: Aug 17, 2022 4:00 PM
0.540
-0.006 (-1.026%)
After-hours: Aug 17, 2022 6:17 PM EDT
13.36%
Market Cap 20.36M
Revenue (ttm) n/a
Net Income (ttm) -37.67M
Shares Out 37.32M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,181,263
Open 0.481
Previous Close 0.481
Day's Range 0.450 - 0.750
52-Week Range 0.393 - 7.000
Beta 0.07
Analysts Buy
Price Target 7.65 (+1,302.1%)
Earnings Date Aug 15, 2022

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of... [Read more...]

Industry Biotechnology
Founded 2003
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ENSC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ENSC stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 1,302.13% from the latest price.

Price Target
$7.65
(1,302.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call

~ Call to be Held Today, August 17, 2022 at 11am ET ~ SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stag...

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

Corporate Update Call to be Held Wednesday, August 17, 2022 SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinica...

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

SAN DIEGO, CA / ACCESSWIRE / August 9, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to ...

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timin...

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~ ~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~ SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce B...

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~ SAN DIEGO, CA / ACCESSWIRE / July 13, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-...

Why Is Ensyce Biosciences (ENSC) Stock Down 27% Today?

Ensyce Biosciences (ENSC) stock is taking a beating on Friday after the clinical-stage biotech company announced $8 million in financing. The post Why Is Ensyce Biosciences (ENSC) Stock Down 27% Today?

Ensysce Biosciences Secures $8 Million Convertible Note Financing

~ Additional Funding from Investor Cohort Validates Company's Mission ~ SAN DIEGO, CA / ACCESSWIRE / July 1, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), ...

Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) P...

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to impro...

Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT SAN DIEGO, CA / ACCESSWIRE / June 21, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a...

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

~ Nasal Opioid Abuse Being Explored for PF614 ~ ~ Data From Trial Expected in September 2022 ~ SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:...

Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage ...

Ensysce Biosciences Releases 2021 Annual Shareholder Letter

SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to imp...

Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101

~ Results confirmed the safety and longer-lasting profile of PF614 versus OxyContin and provides first human data showing the potential for overdose protection with MPAR~ ~ Announces corporate update ca...

Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK

SAN DIEGO, CA / ACCESSWIRE / April 20, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to ...

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to ...

Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

~ Corporate Update Call to be Held Wednesday, April 6, 2022 ~ ~ Corporate Update Call to be Held Wednesday, April 6, 2022 ~

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update ...

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to ...

Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to impr...

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to impr...

Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms desig...

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

SAN DIEGO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms desig...

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may ...

Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop

These five top short squeeze stocks are among the top speculative plays investors and traders are watching in today's market. The post Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Rea...

Other symbols: AVCTISIGRELIPTPI

5 Short Squeeze Candidates To Watch: Insignia Systems, American Virtual Cloud Top List Again, Reliance Global Rejoins

Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: AVCTISIGPTPIRELI

Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid

BE Study of PF614 Provides Critical Step toward FDA Approval BE Study of PF614 Provides Critical Step toward FDA Approval